Collegium Pharmaceutical

About:

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.

Website: http://www.collegiumpharma.com

Top Investors: RA Capital Management, Frazier Healthcare Partners, Longitude Capital, Rock Springs Capital, Eventide

Description:

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

Total Funding Amount:

$309M

Estimated Revenue Range:

$500M to $1B

Headquarters Location:

Stoughton, Massachusetts, United States

Founded Date:

2002-01-01

Contact Email:

info(AT)collegiumpharma.com

Founders:

Jane Hirsch, Michael T. Heffernan

Number of Employees:

101-250

Last Funding Date:

2023-02-07

IPO Status:

Public

© 2025 bioDAO.ai